



Raquel C. Jadulco (Autor)

**Isolation and Structure Elucidation of Bioactive  
Secondary Metabolites from Marine Sponges and  
Sponge-derived Fungi**

Raquel C. Jadulco

---

**Isolation and Structure Elucidation  
of Bioactive Secondary Metabolites  
from Marine Sponges and Sponge-derived Fungi**

---



Cuvillier Verlag Göttingen

<https://cuvillier.de/de/shop/publications/3420>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentzsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen,  
Germany

Telefon: +49 (0)551 54724-0, E-Mail: [info@cuvillier.de](mailto:info@cuvillier.de), Website: <https://cuvillier.de>

## I. Introduction

### 1.1. Significance of the study

#### 1.1.1. The need for lead compounds for drug development


Even today, after more than 100 years of research in pharmaceutical industries, there is still a great need for innovative drugs. Only one third of all diseases can be treated efficiently [Müller *et al.*, 2000]. This means that there is a need for new drug entities to enable therapeutic innovations.

The economic importance of natural products is evident in a conference entitled *Profiting from biodiversity by leveraging natural product discovery*, which took place on 28-29 June 1999 in London. It was highlighted that ten of the top 20 selling medicines in 1998 were derived from natural products [Lawrence, 1999]. It was also claimed that drugs derived from natural products acquire a market share of about 80 billion US \$ in the world pharmaceutical market [Müller *et al.*, 2000]. Furthermore, a study using US-based prescription data from 1993 showed that over 50% of the most-prescribed drugs in the US had a natural product either as the drug, or as a 'forebear' in the synthesis or design of the agent [Grifo *et al.*, 1997], thus demonstrating that natural products still play a major role in drug treatment.

The role of natural products in drug discovery is demonstrated by an analysis of the number and sources of anticancer and antiinfective agents, reported mainly in the Annual Reports of Medicinal Chemistry from 1984 to 1995 [Cragg, 1997]. It was observed that over 60% of the approved drugs and pre-NDA (New Drug Applications) candidates (for the period 1989-1995), excluding biologics (vaccines, monoclonals, etc. derived from mammalian sources), developed in these disease areas are of natural origin.

Drugs of natural origin have been classified as original natural products, products derived semisynthetically from natural products, or synthetic products based on natural product models [Cragg, 1997]. Bioactive natural products could thus serve as

lead structures which could then be 'optimized' through classical medicinal chemistry techniques and the more recent combinatorial synthesis methods to come up with new agents with improved pharmacokinetics and/or toxicology (Fig. 1.1).



A lead compound is a compound with many of the characteristics of a desired new drug which will be used as a model for chemical modification. It must be potent, but it does not need to possess the potency at the nanomolar or picomolar levels expected of a product candidate. It must be specific for the desired target, but it does not need to possess the exquisite biochemical specificity required for a new drug. Finally, it must be available in sufficient quantities to support the early stages of development, such as biological characterization and toxicity studies, while a total synthesis of the product candidates is being completed.

Low-molecular mass natural products from bacteria, fungi, plants and marine organisms exhibit unique structural diversity, and are of maximum interest for identifying new lead structures. Thomas Henkel (Bayer AG, Wuppertal, Germany) reported that most natural products have a higher molecular weight than their synthetic counterparts, containing more rings and being generally more sterically

complex [Lawrence, 1999]. Furthermore, Henkel found that, on comparison of the compounds in a natural product dataset (DNP) with a representative pool of chemical test substances (Synthetics), there was only a 60% homology. Henkel also demonstrated that by comparing the structures of natural products, synthetic drugs, and currently used drugs, there was a much higher incidence of O-containing groups in the natural product compounds. Furthermore, natural product compounds were found to contain more  $sp^3$ -hybridized bridgehead atoms. This illustrates the diverse range of compounds that can be gained from natural products that would otherwise be missed using synthetic techniques.

### 1.1.2. Strategies for drug development from natural products

Generally, strategies for drug discovery can be separated into three categories: chemically driven, biologically driven and a combination of both [McConnell *et al.*, 1994]. In the chemically driven or 'traditional grind-and find' approach, which has been pursued mainly by academic research groups, the object of the search was to find novel compounds from marine sources. Hence, extracts are 'screened' by TLC,  $^1H$  and  $^{13}C$  NMR for unusual and interesting patterns. The next step for this approach is then finding biological properties for purified compounds. The biologically driven strategy is the bioassay-guided approach beginning with crude extracts and has been the preferred method by modern marine natural product researchers.

The biologically driven approach which involves 'screening' crude extracts for biological activity, followed by the crucial work of backtracking the active compounds from the 'hit'-extracts dominate natural products research up to the present. However, a lot of experience is required to exclude both false positive and false negative results. Considerable effort is required to get access to sufficient quantities of raw material for reproduction, isolation, structure elucidation and subsequent verification of biological activity. The complete process proved to be highly time and capacity consuming. Moreover, false positives may result when the activity shown by an extract is attributed to a synergistic effect of more than one constituent in the extract.

It seems advantageous to perform a screening with pure compounds rather than with crude extracts. For individuals, however, the problem arises of getting access to sufficient numbers of natural compounds covering a substantial structural diversity. A new approach utilized by pharmaceutical industries for the discovery of new drugs is the creation of a central natural product pool. With a natural product pool, supplied by the industry and the academic institutions, compounds are getting a more realistic chance to be discovered and highlighted in diverse target directed bioassay systems of therapeutic value. Together with high throughput screening (HTS), a greater number of 'hits' of lead compounds have been identified.

The development of new bioassay methods that can selectively detect biologically active molecules at very low levels as well as the advances in chemical instrumentation (e.g. high performance liquid chromatography (HPLC), high performance centrifugal countercurrent chromatography (HPCCC), capillary zone electrophoresis (CZE), high resolution mass spectrometry (HRMS), high field nuclear magnetic resonance (NMR) and X-ray crystallography which now allow the chemist to isolate submilligram quantities of the new compounds, and confidently be able to fully characterize them and identify their structures contributed to the current peak in interest in natural products.

New bioassays which target receptors and enzymes involved in pathogenesis of disease are being developed. These assays reflect new opportunities due to the recent identification of previously unrecognized biomolecular targets for therapy.

### **1.2. Current status of marine natural product research**

Although natural products research was previously focused mainly on plants, growing interests in marine natural products have led to the discovery of an increasing number of potentially active agents considered worthy for clinical application. The world's oceans cover more than 70% of the earth's surface represent our greatest resource of new natural products [McConnell *et al.*, 1994]. The sea contains well over 200,000 invertebrate and algal species [Ibid]. There exist nearly 150,000 species of algae (sea weed): green (Chlorophyta), red (Rhodophyta), and brown (Phaeophyta), and some groups of marine invertebrates in which new chemical structures or

biological activities have been reported: sponges (Porifera), cnidarians or coelenterates [corals, octocorals (including sea fans), hydroids, and sea anemones], nemerteans (worms), bryozoans, ascidians (tunicates including sea squirts), molluscs (sea snails and sea slugs), and echinoderms (brittlestars, sea urchins, starfish, and sea cucumbers) [Ibid].

The earliest findings include the arabinose-nucleosides, known since the 1950's as constituents of the Caribbean sponge *Cryptotethya crypta* (Tethyidae) which served as lead compounds for the synthesis of analogues, ara-A (Vidarabin, Vidarabin Thilo<sup>®</sup>) and ara-C (Cytarabin, Alexan<sup>®</sup>, Udicil<sup>®</sup>) with improved antiviral and anticancer activity. Since then however, the systematic investigation of marine environments as sources of novel biologically active agents only began in earnest in the mid-1970s. During the decade from 1977-1987, about 2500 new metabolites were reported from a variety of marine organisms [Newman *et al.*, 2000]. Prior to 1995, a total of 6500 marine natural products had been isolated; by January of 1999, this figure had risen to approximately 10,000 [Jaspars, 1999]. These studies have clearly demonstrated that the marine environment is a rich source of bioactive compounds, many of which belong to totally novel chemical classes not found in terrestrial sources.

A recent review provided an updated list of marine natural products which are currently under clinical trials (Table 1) (Fig. 1.2) [Proksch *et al.*, 2002].